染色质状态动态赋予结直肠癌增强子亚型特定治疗策略
该研究通过绘制69份样本的222个染色质图谱,发现H3K27ac标记的活跃增强子状态可区分结直肠癌不同进展阶段,并鉴定出四种增强子亚型(EpiC)。基于EpiC与转录组亚型的关联,研究者提出增强子阻断性溴结构域抑制剂联合通路特异性抑制剂的精准联合治疗策略。
要点
- H3K27ac活跃增强子状态可区分结直肠癌不同进展阶段。
- 肿瘤特异性增强子获得对ASCL2和FZD10等癌基因的过度增殖是必需的。
- 基于增强子图谱的EpiC分型可为精准联合治疗提供依据。
核心结论
- 活跃增强子动态驱动结直肠癌进展,患者特异性增强子模式可用于精准联合治疗。
研究设计与样本
- 研究对69份样本(33例结直肠腺癌、4例腺瘤、21例配对正常组织和11个结肠癌细胞系)绘制了222个染色质图谱,检测六种组蛋白修饰标记。
主要发现
- H3K27ac标记的活跃增强子状态可区分结直肠癌不同进展阶段。
- 表观基因组编辑证据表明,ASCL2和FZD10等关键癌基因的肿瘤特异性增强子获得对过度增殖是必需的。
- MEK联合溴结构域抑制在结直肠癌患者来源异种移植模型中具有协同效应。
- 鉴定出四种不同的增强子亚型(EpiC),其中三种与既往定义的转录组亚型(CMS)相关性良好。
- CMS2可分为两个EpiC亚组,且生存差异显著。
关键数值与推荐
- 检测的六种组蛋白修饰标记为:H3K4me3(Pol II结合及CpG富集启动子)、H3K4me1(蓄势增强子)、H3K27ac(增强子及转录活跃启动子)、H3K79me2(转录区域)、H3K27me3(多梳抑制区域)和H3K9me3(异染色质)。
- 针对EpiC分组设计了增强子阻断性溴结构域抑制剂联合通路特异性抑制剂(PARPi、EGFRi、TGFβi、mTORi和SRCi)的组合治疗策略。
临床怎么用
- 可利用患者特异性增强子模式指导结直肠癌的精准联合治疗。
- MEK联合溴结构域抑制可作为结直肠癌的潜在治疗策略。
- 基于EpiC分型,可考虑溴结构域抑制剂联合PARPi、EGFRi、TGFβi、mTORi或SRCi等通路特异性抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Enhancer aberrations are beginning to emerge as a key epigenetic feature of colorectal cancers (CRC), however, a comprehensive knowledge of chromatin state patterns in tumour progression, heterogeneity of these patterns and imparted therapeutic opportunities remain poorly described. DESIGN: We performed comprehensive epigenomic characterisation by mapping 222 chromatin profiles from 69 samples (33 colorectal adenocarcinomas, 4 adenomas, 21 matched normal tissues and 11 colon cancer cell lines) for six histone modification marks: H3K4me3 for Pol II-bound and CpG-rich promoters, H3K4me1 for poised enhancers, H3K27ac for enhancers and transcriptionally active promoters, H3K79me2 for transcribed regions, H3K27me3 for polycomb repressed regions and H3K9me3 for heterochromatin. RESULTS: We demonstrate that H3K27ac-marked active enhancer state could distinguish between different stages of CRC progression. By epigenomic editing, we present evidence that gains of tumour-specific enhancers for crucial oncogenes, such as ASCL2 and FZD10, was required for excessive proliferation. Consistently, combination of MEK plus bromodomain inhibition was found to have synergistic effects in CRC patient-derived xenograft models. Probing intertumour heterogeneity, we identified four distinct enhancer subtypes (EPIgenome-based Classification, EpiC), three of which correlate well with previously defined transcriptomic subtypes (consensus molecular subtypes, CMSs). Importantly, CMS2 can be divided into two EpiC subgroups with significant survival differences. Leveraging such correlation, we devised a combinatorial therapeutic strategy of enhancer-blocking bromodomain inhibitors with pathway-specific inhibitors (PARPi, EGFRi, TGFβi, mTORi and SRCi) for EpiC groups. CONCLUSION: Our data suggest that the dynamics of active enhancer underlies CRC progression and the patient-specific enhancer patterns can be leveraged for precision combination therapy.
引用
- Orouji E, Raman AT, Singh AK, et al. Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut. 2021. PMID: 34059508. doi:10.1136/gutjnl-2020-322835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。